Updated on 20 October 2026
Medicinal Chemistry & Drug Discovery for Infectious and Neurodegenerative Diseases
Internationalization Research Manager at Centro de Investigaciones Biológicas Margarita Salas-CSIC
Madrid, Spain
About
The Translational Medicinal and Biological Chemistry Group at CIB Margarita Salas (CSIC), [full profile available], brings extensive expertise in drug discovery and early therapeutic development for infectious and neurodegenerative diseases, covering all stages from hit identification to lead optimization and pre‑clinical candidate generation.
The group is a validated chemistry site of the EU-OPENSCREEN ERIC.
Our team combines computational chemistry, molecular modelling, virtual screening, organic synthesis and medicinal chemistry, enabling the efficient design and optimization of small molecules with improved potency, selectivity and pharmacokinetic properties. We work across multiple therapeutic areas and targets, providing advanced capabilities for structure–guided design, SAR analysis, chemical library development and preclinical profiling.
We collaborate extensively in multidisciplinary consortia and are strongly positioned to contribute to Horizon Europe projects requiring expertise in drug discovery pipelines, small‑molecule development, mechanism‑based inhibitor design, or therapeutic innovation in infectious, neurodegenerative or other disease areas where targeted chemical interventions are needed.
Similar opportunities
Project cooperation
Fundación MEDINA –Natural product-based drug discovery expertise for novel small molecule antivirals
- Partner seeks Consortium/Coordinator
- Destination 3: HORIZON-HLTH-2027-01-DISEASE-05: Development of novel small molecule antiviral therapeutics for pathogens with epidemic potential
Mercedes Gallardo
Project Manager at FUNDACIÓN MEDINA
Granada, Spain
Project cooperation
Connecting Disease Biology with Advanced Intervention and Next-Gen Health Solutions
Ioanna Kalograiaki
Internationalization Research Manager at Centro de Investigaciones Biológicas Margarita Salas-CSIC
Madrid, Spain
Project cooperation
MedChem partner proposal on HORIZON-HLTH-2027-01-DISEASE-05 call
- Destination 3: HORIZON-HLTH-2027-01-DISEASE-05: Development of novel small molecule antiviral therapeutics for pathogens with epidemic potential
Cyril B. DOUSSON
CEO at Ai-biopharma
Montpellier, France